Pancreatic squamous cell carcinoma (SCC) is an exceptionally rare tumor that differs fundamentally from the far more common pancreatic ductal adenocarcinoma (PDAC). While PDAC arises from ductal epithelial cells and follows well-characterized genetic pathways involving KRAS, TP53, SMAD4, and CDKN2A mutations, pure SCC of the pancreas has its own distinct biology that is poorly understood due to its rarity.
The term 'squamous' refers to the morphological appearance of the tumor cells: they resemble the flat, scale-like squamous cells normally found in skin and mucous membranes rather than the glandular cells that line the pancreatic ducts. This divergent differentiation suggests that SCC either arises from a different cell of origin or follows a completely different transformation pathway than PDAC.
Because pure pancreatic SCC is so rare, virtually no published genomic data existed prior to this study. Without molecular characterization, tailoring therapy or identifying drugable targets for this cancer is impossible - making genomic profiling of even a handful of cases scientifically valuable.
The research team retrospectively reviewed 1,033 pancreatic cancer cases to identify patients with pure squamous cell carcinoma - a process that required careful pathological review to exclude tumors with mixed histology or adenosquamous differentiation, which are themselves rare but more common than pure SCC.
Only two pure SCC cases (0.19%) were identified from this large screened population, underscoring the extreme rarity of the tumor type. This prevalence figure is itself an important contribution to the literature, providing the first rigorous estimate of how often pure SCC occurs among pancreatic cancers.
Genomic profiling was performed using a 137-gene high-throughput sequencing (HTS) panel that captures single-nucleotide variants (SNVs) and small insertions and deletions (InDels) across cancer-relevant genes. HTS panels targeting known cancer genes offer a cost-effective way to characterize the mutational landscape of rare tumors where whole-exome sequencing of large cohorts is not feasible.
The genomic analysis revealed mutations in several genes not typically associated with PDAC, including DNHD1, OR51Q1, PTPRD, TCF4, and TET2. The absence of common PDAC driver mutations (such as KRAS mutations) in the profiled cases further supports the idea that pancreatic SCC arises through a fundamentally different molecular pathway than conventional pancreatic adenocarcinoma.
PTPRD encodes a receptor-type protein tyrosine phosphatase that functions as a tumor suppressor in several cancer types by regulating cell adhesion and signaling pathways. Loss of PTPRD function has been described in head and neck squamous cell carcinoma, lung cancer, and glioblastoma, suggesting a potential shared mechanism of squamous transformation across different tissue types.
TET2 is an epigenetic regulator involved in DNA demethylation. TET2 mutations are commonly found in hematological malignancies and are increasingly recognized in solid tumors. Its presence in pancreatic SCC suggests that epigenetic dysregulation may play a role in squamous transformation of pancreatic cells, opening a potential avenue for epigenetic therapy.
The mutation profile of the two pancreatic SCC cases showed some overlap with the genomic landscapes of squamous cell carcinomas arising in other organs, particularly head and neck SCC and lung squamous cell carcinoma. This suggests a degree of shared molecular logic underlying squamous transformation regardless of tissue origin, which could be exploited therapeutically.
If pancreatic SCC shares key molecular drivers with more common squamous cancers, then drugs already approved for head and neck or lung SCC - such as EGFR inhibitors and immune checkpoint inhibitors - might have activity in pancreatic SCC. The rarity of the tumor makes conventional randomized trials impossible, but knowledge of genomic overlap provides a scientific rationale for empirical trials of these agents.
Conversely, the unique mutations found only in pancreatic SCC (such as DNHD1 and OR51Q1) may reflect either the particular cell of origin within the pancreas or tissue-specific co-selection pressures. Functional studies in cell lines and animal models would be needed to establish whether these mutations are genuine drivers or passenger events in the tumor's evolution.
This study demonstrates the value of thorough molecular characterization even when patient numbers are tiny. For ultra-rare tumors like pancreatic SCC, case-level genomic profiling is currently the only feasible way to generate biological hypotheses that can guide treatment decisions for future patients with the same diagnosis.
The findings argue for routine genomic profiling of all pancreatic tumors with unusual histology at the time of diagnosis. When pathological review reveals squamous or adenosquamous differentiation, immediate HTS panel testing would identify any actionable mutations or therapeutic overlaps with better-characterized squamous cancers, potentially opening options beyond standard PDAC chemotherapy protocols.
As cancer genomic databases grow through international collaborative efforts, pooling genomic data from rare tumor types across many institutions will eventually enable analyses of larger SCC cohorts. This incremental accumulation of molecular knowledge - even from individual case reports and small series - is how the field ultimately builds the evidence base needed to develop evidence-guided treatment protocols for patients with otherwise untreatable rare malignancies.